EuropaWire20d
AstraZeneca Presents New Data at IDWeek 2024, Showcasing Progress in Respiratory Disease Prevention and Vaccine Innovation
(IN BRIEF) AstraZeneca presented significant advancements in the prevention of infectious diseases at IDWeek 2024, showcasing its dedication to addressing respiratory infections caused by RSV, hMPV, ...
2minutemedicine.com22d
AstraZeneca’s FluMist first and only self-administered flu vaccine
FluMist is an efficacious and safely tolerated intranasal influenza vaccine. FluMist has gained approval from the FDA for self-administration by patients aged 18-49. FluMist is the first influenza ...
Morningstar26d
AstraZeneca Holds a Strong Portfolio and Pipeline That Support Solid Long-Term Growth
AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that add up to a wide moat. The strong replenishment of new drugs ...
Outsourcing-pharma26d
AstraZeneca licenses CSPC’s cardiovascular drug in $2 billion deal
The big pharma company AstraZeneca has forged a licensing pact worth $2 billion with the Chinese firm CSPC Pharmaceutical Group for access to an experimental small molecule treatment for dyslipidemia.
Chemistry World27d
AstraZeneca synthetic chemistry prize winner celebrates ‘culmination of a high-quality academia-industry collaboration’
The 2024 AstraZeneca prize in synthetic chemistry has been awarded to Ruth Webster, University of Cambridge, for her productive early career and innovative research, particularly in iron catalysis, ...
FinanceAsia28d
AstraZeneca signs license agreement with China’s CSPC worth up to $2bn
UK pharmaceutical giant AstraZeneca has entered into an exclusive license agreement with China's CSPC Pharmaceutical Group (CSPC) to advance the development of an early stage, novel small molecule ...
Yahoo Finance28d
Astrazeneca (AZN) Loses -5.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Astrazeneca (AZN) has been beaten down lately with too much selling pressure. While the stock has lost 5.3% over the past four weeks, there is light at the end of the tunnel as it is now in ...
Yahoo Finance29d
AstraZeneca Inks Agreement to Boost Cardiovascular Pipeline
AstraZeneca AZN announced that it has signed an exclusive license agreement with China-based CSPC Pharmaceutical Group Ltd for developing an early-stage, small molecule Lipoprotein (a) (Lp(a ...
PharmiWeb29d
AstraZeneca strengthens its cardiovascular pipeline with agreement for a pre-clinical novel lipid-lowering therapy
AstraZeneca has entered into an exclusive license agreement with CSPC Pharmaceutical Group Ltd (CSPC) to advance the development of an early stage, novel small molecule Lipoprotein (a) (Lp(a)) ...
clinicaltrialsarena29d
AstraZeneca’s Phase III trial of treatment for asthma meets its primary endpoint
AstraZeneca’s Airsupra is currently approved in the US for as-needed treatment or prevention of bronchoconstriction. Credit: Jennie Book/Shutterstock. UK-based pharmaceutical company AstraZeneca has ...
Business Times29d
AstraZeneca signs US$1.92 billion licensing deal with HK-listed CSPC
AstraZeneca said on Monday (Oct 7) it would pay up to US$1.92 billion to CSPC Pharmaceutical Group in an exclusive licence agreement to boost the Anglo-Swedish drugmaker’s cardiovascular pipeline.